Acumen Pharmaceuticals Inc 2025年度报告

FORM 10-K xAnnual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or oTransition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934FOR THE TRANSITION PERIOD FROMTOCommission file number: 001-40551__________________________ Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)__________________________ 36-4108129 (I.R.S. EmployerIdentification No.) (State or other jurisdiction ofincorporation or organization) Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.oYesxNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.xYesoNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).xYesoNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated fileroNon-accelerated filerxEmerging growth companyx Accelerated filero Smaller reporting companyx If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by theregistered public accounting firm that prepared or issued its audit report.o If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statementso Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).oYesxNo The aggregate market value of the common stock of the registrant held by non-affiliates of the registrant as of June 30, 2025, thelast business day of the registrant’s second fiscal quarter, was $45.3 million. The number of the registrant’s shares of common stock outstanding as of March 20, 2026 was 72,212,758. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement relating to its 2026 annual meeting of the shareholders, or the 2026 ProxyStatement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2026 Proxy Statementwill be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this reportrelates. TABLE OF CONTENTS PagePART I..........................................................................................................................................................................1ITEM 1.BUSINESS.........................................................................................................................................1ITEM 1A.RISK FACTORS................................................................................................................................27ITEM 1B.UNRESOLVED STAFF COMMENTS............................................................................................77ITEM 1C.CYBERSECURITY...........................................................................................................................78ITEM 2.PROPERTIES....................................................................................................................................78ITEM 3.LEGAL PROCEEDINGS..................................................................................................................78ITEM 4.MINE SAFETY DISCLOSURES......................................................................................................79PART II............................................................................................